Tvardi Therapeutics, Inc. (TVRD)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Total revenue | - | 2,569 | ||
| Research and development | 5,806 | 319 | ||
| General and administrative | 3,063 | 4,636 | ||
| Total operating expenses | 8,869 | 4,955 | ||
| Loss from operations | -8,869 | -2,386 | ||
| Interest income | 377 | - | ||
| Other income, net | 12,659 | 347 | ||
| Non-cash interest expense on liability related to sales of future royalties and milestones | - | 2,867 | ||
| Net income (loss) | 4,167 | -4,906 | ||
| Unrealized loss on short-term investments | -15 | - | ||
| Comprehensive income (loss) | 4,152 | -4,906 | ||
| Earnings per share, basic | 0.51 | -3.22 | ||
| Earnings per share, diluted | -1 | -3.22 | ||
| Weighted average number of shares outstanding, basic | 8,246,582 | 1,524,116 | ||
| Weighted average number of shares outstanding, diluted | 8,455,223 | 1,524,116 | ||